Novo Nordisk: Redefine 4 Misses The Mark

As you know, Novo Nordisk ( NVO ) has just released top-line results from its REDEFINE 4 Phase 3 obesity trial. Overall, the results are clearly a disappointment relative toI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave me an appreciation for the rigor and challenges behind drug devel ...